Shukra Pharmaceuticals Ltd Announces Direct Listing on National Stock Exchange
Shukra Pharmaceuticals Limited, a significant entity in the pharmaceutical manufacturing sector, has announced that its equity shares have been approved for listing and regular trading on the Main Board of the National Stock Exchange of India Limited (NSE). The company is transitioning to the NSE via a direct listing from the Bombay Stock Exchange (BSE), marking a major milestone.The landmark event, including the ceremonial opening bell ringing at the NSE Exchange Plaza in Mumbai, is scheduled for Friday, August 14, 2026. This dual-listing strategy aims to expand the company's visibility, attract a broader base of institutional and retail investors, and deepen market liquidity across platforms.
To facilitate precision in order routing and assist institutional participants, the trading identifiers for Shukra Pharmaceuticals Limited on the NSE platform have been provided:
| Identifier | Detail |
|---|---|
| BSE Code | 524632 |
| NSE Trading Symbol | SHUKRAPHAR |
| ISIN | INE551C01044 |
| Market Segment | Main Board - Equity (Normal Rolling Market) |
| Base Reference Price | Derived from the closing price on the BSE on August 13, 2026. |
Corporate Vision and Growth Strategy
Dakshesh Shah, Managing Director of Shukra Pharmaceuticals Limited, stated that the listing on the National Stock Exchange represents a major milestone reflecting the company's strong financial health and operational scaling. He emphasized that trading on the NSE is instrumental in expanding the firm's reach to institutional investors and increasing market liquidity, moving them closer to their goal of becoming a premier name in global pharmaceutical manufacturing.The Managing Director noted that as a dual-listed entity, Shukra Pharmaceuticals offers a more accessible platform for new investors and remains committed to driving sustainable, long-term value.
Company Profile
Shukra Pharmaceuticals Limited is an India based pharmaceutical company specializing in the manufacturing and marketing of generic pharmaceutical formulations. Operating with state of the art facilities compliant with current good manufacturing practices (cGMP), the company manufactures tablets, capsules, and liquid injections. Its products cater to both domestic public healthcare demands and international distribution networks.SHUKRAPHAR Stock Price Movement
As of 12:11 PM, shares of Shukra Pharmaceuticals Limited are shedding 2.55% in live trading, currently priced at ₹40.2 as the stock declines by ₹1.05. The downward move takes place amid active market interest, with the company seeing a trade volume of 631,054 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.